C07D207/448

Polymerizable compound and composition, liquid crystal composite, optical anisotropic body, liquid crystal display device and use thereof

Provided are a polymerizable compound having at least one monovalent group (A), a polymerizable composition containing the polymerizable compound, a liquid crystal composite prepared from the polymerizable composition, and a liquid crystal device having the polymerizable composition. ##STR00001## In monovalent group (A), R.sup.1 and R.sup.2 are independently hydrogen, halogen or alkyl having 1 to 20 carbons, and in the alkyl, at least one piece of —CH.sub.2— may be replaced by —O— or —S—, and at least one piece of —(CH.sub.2).sub.2— may be replaced by —CH═CH—, and in the groups, at least one hydrogen may be replaced by halogen.

Method for purifying N-substituted maleimide

The present invention relates to a method for purifying N-substituted maleimide. More particularly, the present invention adopts an evaporation apparatus, which can previously remove impurities having higher boiling points than the N-substituted maleimide after removing an organic solvent from an N-substituted maleimide resulting solution, thereby achieving effects of minimizing the pressure loss and polymerization loss, and obtaining high-purity N-substituted maleimide.

METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
20230286914 · 2023-09-14 ·

The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.

METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
20230286914 · 2023-09-14 ·

The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.

CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

COMPOSITION, FILM, ORGANIC LIGHT EMITTING ELEMENT, METHOD FOR PROVIDING LIGHT EMITTING COMPOSITION, AND PROGRAM
20230119624 · 2023-04-20 ·

An organic light emitting element produced by using a light emitting composition that contains both a first compound having a PBHT value more than 0.730 and a second compound having ES1 lower than that of the first compound and AEsT less than 0.20 eV is excellent in durability. ES1 is the lowest excited singlet energy level, AEsT is the difference between the lowest excited singlet energy level and the lowest excited triplet energy level.

Method for manufacturing methacrylic resin composition

Provided is a method for manufacturing a methacrylic resin composition having excellent surface processability and displaying excellent preservability of formed surface processing. A method for manufacturing a methacrylic resin composition, wherein the methacrylic resin composition comprises two or more types of methacrylic resins that each have a structural unit (X) having the same type of cyclic structure-containing main chain, the methacrylic resin composition has a Vicat softening temperature of 120° C. to 160° C., methanol-soluble content is contained in an amount of 5 mass % or less relative to 100 mass %, in total, of the methanol-soluble content and methanol-insoluble content, comprising mixing a low molecular weight component and a high molecular weight component.

Method for manufacturing methacrylic resin composition

Provided is a method for manufacturing a methacrylic resin composition having excellent surface processability and displaying excellent preservability of formed surface processing. A method for manufacturing a methacrylic resin composition, wherein the methacrylic resin composition comprises two or more types of methacrylic resins that each have a structural unit (X) having the same type of cyclic structure-containing main chain, the methacrylic resin composition has a Vicat softening temperature of 120° C. to 160° C., methanol-soluble content is contained in an amount of 5 mass % or less relative to 100 mass %, in total, of the methanol-soluble content and methanol-insoluble content, comprising mixing a low molecular weight component and a high molecular weight component.

METHOD FOR PURIFYING N-SUBSTITUTED MALEIMIDE
20210355083 · 2021-11-18 ·

The present invention relates to a method for purifying N-substituted maleimide. More particularly, the present invention adopts an evaporation apparatus, which can previously remove impurities having higher boiling points than the N-substituted maleimide after removing an organic solvent from an N-substituted maleimide resulting solution, thereby achieving effects of minimizing the pressure loss and polymerization loss, and obtaining high-purity N-substituted maleimide.

Bismaleimide modified product and method for producing the same

An object of the present invention is to provide a bismaleimide (D-BMI) modified product in which an amino group of dimer diamine (DDA) is maleimidized, which has the good heat resistance, and has the sufficiently enhanced processability, and a method for producing the same. There are provided: <1> A bismaleimide (D-BMI) modified product in which an amino group of dimer diamine is maleimidized, the bismaleimide modified product having the following characteristics: 1) An acid value of the D-BMI modified product is 2 mg-KOH/g or less. 2) In .sup.1H-NMR, when quantitative comparison is performed using an integrated value (A) of a peak corresponding to a proton of a methylene group directly bound to a nitrogen atom of a maleimide group and an integrated value (B) of a peak corresponding to a vinyl proton of a maleimide group, A/B is 1.25 or more and 2.00 or less. <2> A method for producing D-BMI, the method including the following steps: 1) A step of preparing a crude D-BMI solution having an acid value of more than 2 mg-KOH/g. 2) A step of lowering an acid value of D-BMI to 2 mg-KOH/g or less by reacting an acid component in the solution with a carbodiimide compound. 3) A step of reacting the solution without a catalyst at 110 to 200° C. in a solvent.